Spero Therapeutics Confirms June 18 PDUFA Date for Tebipenem HBr, Extends Cash Runway into 2028

summarizeSummary

Spero Therapeutics announced its first quarter 2026 results, confirming the June 18, 2026 PDUFA date for tebipenem HBr and extending its cash runway guidance into 2028, following an improved net loss.

check_boxKey Events

• PDUFA Date Confirmed for Tebipenem HBr

  The FDA's Prescription Drug User Fee Act (PDUFA) date for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections (cUTI), is confirmed for June 18, 2026. The Phase 3 PIVOT-PO trial was stopped early for efficacy, demonstrating non-inferiority.

• Cash Runway Extended into 2028

  Spero Therapeutics maintains its cash and cash equivalents of $56.1 million as of March 31, 2026, are sufficient to fund operations into 2028, providing significant financial stability.

• Improved First Quarter 2026 Financials

  The company reported a net loss of $7.2 million for Q1 2026, a notable improvement compared to a net loss of $13.9 million for the same period in 2025, driven by decreased research and development and general and administrative expenses.

auto_awesomeAnalysis

This filing is highly important for Spero Therapeutics as it confirms the Prescription Drug User Fee Act (PDUFA) date of June 18, 2026, for its lead asset, tebipenem HBr. The drug, intended for complicated urinary tract infections, previously demonstrated non-inferiority in a Phase 3 trial that was stopped early for efficacy, significantly de-risking the approval process. Additionally, the company reported an improved net loss for Q1 2026 and, critically for a biotech, extended its cash runway guidance into 2028, providing financial stability ahead of the potential FDA decision.